rupatadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H1 receptor antagonists, tricyclic compounds	2413	158876-82-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rupatadine fumarate rupatadine alergoliber pafinur rinialer rupafin rupax	Rupatadine is a second-generation antihistamine, long-acting histamine antagonist with selective peripheral H1-receptor and platelet activating factor (PAF) antagonistic activities. Some of the metabolites (desloratadine and its hydroxylated metabolites) retain an antihistaminic activity and may partially contribute to the overall efficacy of the drug, maintaining activity for up to 24 hours. Molecular weight: 415.97 Formula: C26H26ClN3 CLOGP: 5.06 LIPINSKI: 1 HAC: 3 HDO: 0 TPSA: 29.02 ALOGS: -4.88 ROTB: 2

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rupatadine fumarate
rupatadine
alergoliber
pafinur
rinialer
rupafin
rupax

Rupatadine is a second-generation antihistamine, long-acting histamine antagonist with selective peripheral H1-receptor and platelet activating factor (PAF) antagonistic activities. Some of the metabolites (desloratadine and its hydroxylated metabolites) retain an antihistaminic activity and may partially contribute to the overall efficacy of the drug, maintaining activity for up to 24 hours.

Molecular weight: 415.97
Formula: C26H26ClN3
CLOGP: 5.06
LIPINSKI: 1
HAC: 3
HDO: 0
TPSA: 29.02
ALOGS: -4.88
ROTB: 2

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 27, 2017	PMDA	Teikoku Seiyaku

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	409.38	31.44	231	5790	165571	63317430
Asthma	216.28	31.44	140	5881	127421	63355580
Ear pruritus	190.20	31.44	49	5972	3916	63479085
Pulmonary function test abnormal	188.86	31.44	42	5979	1788	63481213
Nasal polyps	183.24	31.44	52	5969	5987	63477014
Wheezing	171.97	31.44	109	5912	95486	63387515
Chest X-ray abnormal	169.39	31.44	46	5975	4503	63478498
Sneezing	158.43	31.44	61	5960	18157	63464844
Angioedema	151.52	31.44	79	5942	47886	63435115
Blood lactic acid increased	149.25	31.44	46	5975	7040	63475961
Eye pruritus	139.44	31.44	56	5965	18615	63464386
Upper-airway cough syndrome	139.07	31.44	49	5972	11369	63471632
Lacrimation increased	130.68	31.44	55	5966	20576	63462425
Breath sounds abnormal	129.50	31.44	46	5975	10927	63472074
Full blood count abnormal	128.90	31.44	62	5959	31655	63451346
Rhinitis allergic	122.79	31.44	45	5976	11682	63471319
Platelet count increased	118.16	31.44	49	5972	17662	63465339
Skin plaque	114.03	31.44	39	5982	8281	63474720
Vasculitis	97.11	31.44	43	5978	18166	63464835
Chest discomfort	91.79	31.44	79	5942	109890	63373111
Nasal congestion	91.63	31.44	64	5957	65596	63417405
Eosinophilia	90.96	31.44	44	5977	22712	63460289
Rhinorrhoea	89.37	31.44	63	5958	65514	63417487
Pruritus	77.00	31.44	129	5892	361324	63121677
Cough	73.99	31.44	113	5908	292630	63190371
Blood potassium decreased	73.11	31.44	47	5974	41979	63441022
Sleep disorder due to a general medical condition	62.46	31.44	28	5993	12160	63470841
Anaphylactic reaction	62.35	31.44	51	5970	66049	63416952
Vascular access site thrombosis	45.15	31.44	7	6014	36	63482965
Swelling face	43.78	31.44	41	5980	63434	63419567
Vascular access site infection	42.59	31.44	7	6014	55	63482946
Dysphemia	42.42	31.44	14	6007	2661	63480340
Blood immunoglobulin E increased	41.12	31.44	15	6006	3834	63479167
Lipohypertrophy	40.73	31.44	10	6011	655	63482346
Muscle tension dysphonia	39.84	31.44	8	6013	206	63482795
Chronic spontaneous urticaria	39.80	31.44	11	6010	1146	63481855
Perfume sensitivity	38.84	31.44	10	6011	795	63482206
Paranasal sinus inflammation	38.36	31.44	9	6012	486	63482515
Therapeutic product effect incomplete	36.86	31.44	52	5969	125004	63357997
Oropharyngeal discomfort	36.57	31.44	15	6006	5245	63477756
Dyspnoea	36.46	31.44	141	5880	661172	62821829
Obstructive airways disorder	35.60	31.44	23	5998	20676	63462325
Paraesthesia oral	34.61	31.44	22	5999	19234	63463767
Mast cell activation syndrome	33.79	31.44	9	6012	816	63482185
Oral pruritus	32.40	31.44	11	6010	2280	63480721
Oropharyngeal spasm	31.86	31.44	7	6014	281	63482720

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	85.92	37.89	44	1337	62333	34893217
Obstructive airways disorder	83.79	37.89	29	1352	15465	34940085
Pleural thickening	81.64	37.89	14	1367	371	34955179
Asthma	70.22	37.89	34	1347	42622	34912928
Bronchial wall thickening	63.92	37.89	14	1367	1354	34954196
Nasal oedema	55.33	37.89	10	1371	360	34955190
Upper-airway cough syndrome	55.27	37.89	15	1366	3543	34952007
Full blood count abnormal	46.88	37.89	20	1361	18648	34936902
Pulmonary function test decreased	45.99	37.89	14	1367	4961	34950589
Bronchial obstruction	40.64	37.89	10	1371	1606	34953944

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	473.20	27.53	259	6893	184942	79552294
Asthma	263.96	27.53	159	6993	134936	79602300
Upper-airway cough syndrome	196.34	27.53	63	7089	11630	79725606
Ear pruritus	191.08	27.53	49	7103	4066	79733170
Nasal polyps	184.94	27.53	54	7098	7273	79729963
Wheezing	169.49	27.53	114	7038	116550	79620686
Pulmonary function test abnormal	157.05	27.53	42	7110	4102	79733134
Chest X-ray abnormal	146.92	27.53	46	7106	7837	79729399
Sneezing	146.53	27.53	58	7094	19625	79717611
Full blood count abnormal	144.06	27.53	71	7081	40403	79696833
Angioedema	141.79	27.53	87	7065	75948	79661288
Lacrimation increased	139.08	27.53	58	7094	22419	79714817
Eye pruritus	133.76	27.53	55	7097	20515	79716721
Blood lactic acid increased	125.26	27.53	46	7106	12698	79724538
Rhinitis allergic	123.23	27.53	45	7107	12224	79725012
Rhinorrhoea	119.22	27.53	78	7074	75996	79661240
Breath sounds abnormal	115.12	27.53	46	7106	15938	79721298
Platelet count increased	109.67	27.53	49	7103	22357	79714879
Nasal congestion	109.12	27.53	74	7078	76478	79660758
Pruritus	107.35	27.53	153	6999	394495	79342741
Skin plaque	106.39	27.53	39	7113	10706	79726530
Vasculitis	95.17	27.53	46	7106	25056	79712180
Chest discomfort	87.66	27.53	83	7069	137961	79599275
Cough	75.37	27.53	125	7027	366664	79370572
Blood potassium decreased	73.57	27.53	48	7104	46464	79690772
Obstructive airways disorder	71.65	27.53	41	7111	31418	79705818
Eosinophilia	64.96	27.53	44	7108	45301	79691935
Anaphylactic reaction	56.27	27.53	52	7100	83691	79653545
Chronic spontaneous urticaria	54	27.53	14	7138	1210	79736026
Swelling face	47.40	27.53	44	7108	71168	79666068
Vascular access site thrombosis	45.37	27.53	7	7145	37	79737199
Therapeutic product effect incomplete	44.46	27.53	59	7093	141586	79595650
Bronchial wall thickening	43.36	27.53	14	7138	2627	79734609
Pleural thickening	41.69	27.53	14	7138	2968	79734268
Lip swelling	41.03	27.53	32	7120	40879	79696357
Sleep disorder due to a general medical condition	39.05	27.53	21	7131	14256	79722980
Lipohypertrophy	38.46	27.53	10	7142	874	79736362
Vascular access site infection	37.74	27.53	7	7145	124	79737112
Conjunctivitis allergic	36.10	27.53	11	7141	1709	79735527
Blood immunoglobulin E increased	35.76	27.53	15	7137	5867	79731369
Perfume sensitivity	33.72	27.53	9	7143	870	79736366
Dyspnoea	33.18	27.53	158	6994	856867	78880369
Nasal oedema	31.86	27.53	10	7142	1714	79735522
Mast cell activation syndrome	30.62	27.53	8	7144	712	79736524
Acute kidney injury	30.55	27.53	5	7147	519399	79217837
Food allergy	29.82	27.53	16	7136	10808	79726428
Oropharyngeal discomfort	29.79	27.53	14	7138	7152	79730084
Muscle tension dysphonia	29.73	27.53	6	7146	168	79737068
Stress	29.44	27.53	36	7116	79576	79657660
Idiopathic urticaria	29.33	27.53	6	7146	180	79737056
Frustration tolerance decreased	29.18	27.53	14	7138	7488	79729748
Pulmonary function test decreased	28.94	27.53	14	7138	7623	79729613
Tender joint count	28.63	27.53	6	7146	203	79737033
Dysphemia	28.49	27.53	11	7141	3473	79733763
Swollen tongue	27.73	27.53	26	7126	42544	79694692
Nasal disorder	27.65	27.53	11	7141	3758	79733478

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AX28	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Allergic rhinitis	indication	61582004
Urticaria	indication	126485001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.22	Basic
pKa2	3.82	Basic
pKa3	3.17	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	IC50	8.41		CHEMBL	KEGG DRUG
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		IC50	5.43		CHEMBL

External reference:

ID	Source
D07407	KEGG_DRUG
182349-12-8	SECONDARY_CAS_RN
C0534301	UMLSCUI
CHEBI:135673	CHEBI
CHEMBL91397	ChEMBL_ID
DB11614	DRUGBANK_ID
C103639	MESH_SUPPLEMENTAL_RECORD_UI
133017	PUBCHEM_CID
10103	IUPHAR_LIGAND_ID
7443	INN_ID
2AE8M83G3E	UNII
013131	NDDF
013132	NDDF
1162935008	SNOMEDCT_US
1162955009	SNOMEDCT_US
699252008	SNOMEDCT_US

Pharmaceutical products:

None